title: HIT complicating fondaparinux prophylaxis: fondaparinux-dependent platelet activation as a marker for fondaparinux-induced HIT.
authors.affiliation: Ted Warkentin, MD, Room 1-180A, Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences (Hamilton General Site), 237 Barton Street East, Hamilton, ON L8L 2X2, Canada, E-mail: twarken@mcmaster.ca.
authors.forename: T E
authors.initials: TE
authors.lastname: Warkentin
authors.forename: J-A I
authors.initials: JA
authors.lastname: Sheppard
authors.forename: J C
authors.initials: JC
authors.lastname: Manheim
mesh_terms: D000368:Aged; D000906:Antibodies / Q000097:blood; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000188:drug therapy*; D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000379:methods; D000077425:Fondaparinux; D006801:Humans; D008297:Male; D015539:Platelet Activation / Q000187:drug effects*; D010976:Platelet Count; D011134:Polysaccharides / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D011237:Predictive Value of Tests; D012720:Severity of Illness Index; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology
chemical_list: D000906:Antibodies; D000925:Anticoagulants; D015415:Biomarkers; D011134:Polysaccharides; D014859:Warfarin; D000077425:Fondaparinux